Gabapentin Relonchem 50mg/ml Oral Solution

The Medicines and Healthcare products Regulatory Agency (MHRA) has published a class 4 medicines defect notification.

Relonchem Limited has informed the MHRA that particles have been observed inside some bottles of Gabapentin Relonchem Oral Solution, identified through a customer complaint. Pharmacists are advised to review the information contained within the notification and take this into account when dispensing this product.

Further information, advice and details of the affected batches can be found on the MHRA website.